Quantcast

The Global Pain Therapeutics Market, 2019: GPCR & Nerve Growth Factor-based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pain:
GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in
Difficult-to-Treat Subtypes”
report has been added to ResearchAndMarkets.com’s
offering.

The pain therapeutics market has been largely characterized by only
incremental product innovation over the last decade, as most market
segments continue to be dominated by long-established active
pharmaceutical ingredients and mechanisms of action.

The moderate-to-severe pain space continues to be dominated by opioids,
which are increasingly being reformulated to offer abuse resistance,
whereas mild pain is effectively treated with non-steroidal
anti-inflammatory drugs (NSAIDs). However, significant unmet needs
remain, as chronic pain subtypes-particularly neuropathic pain-do not
respond well to existing therapies.

This report assesses first-in-class innovation across the pain pipeline.

Scope

  • There are 909 pipeline programs in active development for pain. What
    proportion of these products are first-in-class? How does
    first-in-class innovation vary by development stage and molecular
    target class?
  • The market for pain treatment is heavily saturated. Which drug classes
    are used to treat pain? How do the drug classes in the market compare
    with those in the pipelines?
  • Which molecular target classes are prominently represented in the
    first-in-class pain pipelines? Which first-in-class targets have been
    identified as most promising for the treatment of pain? Which
    first-in-class products have prior deal involvement?

Reasons to Buy

  • Understand the current disease landscape with an overview of etiology,
    pathophysiology, disease classification and staging systems and
    epidemiology for major pain subtypes.
  • Visualize the composition of the pain market in terms of dominant
    molecule types and molecular targets. This knowledge allows a
    competitive understanding of gaps in the current market.
  • Analyze and compare the pain pipeline and stratify by stage of
    development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a
    proprietary matrix, first-in-class products have been assessed and
    ranked according to clinical potential. Promising first-in-class
    targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class
    pipeline products for pain that have not yet been involved in
    licensing or co-development deals, and by analyzing company strategies
    in prior deals through case studies of key deals for first-in-class
    pain products.

Topics Covered

1 List of Tables & Figures

2 Pain: Executive Summary

2.1 Substantial Unmet Needs Remain in Core Therapy Types

2.2 Highly Diversified Range of Innovative Programs in the Early Pipeline

3 Introduction

3.1 Catalyst

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Classification

4.3 Sustained Innovation in Pain

4.4 Epidemiology for Pain

4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.3 Pipeline by Molecular Target

5.4 Comparative Distribution of Programs Between Pain Market and
Pipeline by Therapeutic Target Family

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class
Pipeline Programs by Molecular Target Class

5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target
Within the Pipeline

6 First-in-Class Molecular Target Evaluation

6.1 Overview

6.2 Pipeline Programs Targeting Neurotensin Receptor 1

6.3 Pipeline Programs Targeting Matrix Metalloproteinase-9/2

6.4 Pipeline Programs Targeting Beta Nerve Growth Factor

6.5 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating
Polypeptide Type I Receptor

6.6 Pipeline Programs Targeting Interleukin-1 Receptor Type 2

6.7 Pipeline Programs Targeting Metabotropic Glutamate Receptor 7

6.8 Pipeline Programs Targeting Transient Receptor Potential Vanilloid
Type 4

6.9 Pipeline Programs Targeting P2X Purinoceptor 7

6.10 Pipeline Programs Targeting Potassium Channel Subfamily K Member 2

7 Key Players and Deals

7.1 Overview

8 Appendix

8.1 Bibliography

8.2 Abbreviations

8.3 Methodology

List of Tables

Table 1: Etiology of Chronic Pain

Table 2: Classification of Pain

Table 3: Fibromyalgia, Total Prevalent Cases, millions (N), 2013-2023

Table 4: Migraine, Total Prevalent Cases, millions (N), 2016-2026

Table 5: Painful Diabetic Neuropathy, Total Prevalent Cases, millions
(N), 2016-2026

Table 6: Trigeminal Neuralgia, Total Prevalent Cases, millions (N),
2012-2022

List of Figures

Figure 1: Pain, Global Market by Molecular Target and Molecule Type, 2019

Figure 2: Pain, Global, Pipeline by Stage of Development and Molecule
Type, 2019

Figure 3: Pain, Global, Pipeline by Molecular Target and Stage of
Development, 2019

Figure 4: Pain, Global, Distribution of Pipeline and Marketed Products
by Molecular Target Class, 2019

Figure 5: Pain, Global, Distribution of Pipeline Products by
First-in-Class Status and Molecular Target Class, 2019

Figure 6: Pain, Global, Percentage Distribution of First-in-Class and
Non-First-in-Class Products by Stage of Development and Molecular Target
Class, 2019

Figure 7: Pain, Global, Ratio of First-in-Class and Non-First-in-Class
Products to First-in-Class Targets by Stage of Development and Molecular
Target Class, 2019

For more information about this report visit https://www.researchandmarkets.com/r/v6qcs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.